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Abstract
Background:  Osteopontin (OPN) is a secreted phosphoprotein which functions as a cell
attachment protein and cytokine that signals through two cell adhesion molecules, avb3-integrin
and CD44, to regulate cancer growth and metastasis. However, the signaling pathways associated
with OPN have not been extensively characterized. In an in vivo xenograft model of MDA-MB-231
human breast cancer, we have previously demonstrated that ablation of circulating OPN with an
RNA aptamer blocks interaction with its cell surface receptors to significantly inhibit adhesion,
migration and invasion in vitro and local progression and distant metastases.
Findings: In this study, we performed microarray analysis to compare the transcriptomes of
primary tumor in the presence and absence of aptamer ablation of OPN. The results were
corroborated with RT-PCR and Western blot analysis. Our results demonstrate that ablation of
OPN cell surface receptor binding is associated with significant alteration in gene and protein
expression critical in apoptosis, vascular endothelial growth factor (VEGF), platelet derived growth
factor (PDGF), interleukin-10 (IL-10), granulocyte-macrophage colony stimulating factor (GM-CSF)
and proliferation signaling pathways. Many of these proteins have not been previously associated
with OPN.
Conclusion: We conclude that secreted OPN regulates multiple signaling pathways critical for
local tumor progression.
Findings
Osteopontin (OPN), is a secreted phosphoprotein which
signals through avb3-integrin and CD44 to increase cellu-
lar migratory and invasive behavior, increase metastasis,
promote colony formation and 3D growth ability, induce
tumor-associated inflammatory cells, and induce expres-
sion of angiogenic factors. [1-3] Gain- and loss-of func-
tion assays have demonstrated a critical role for OPN in
tumor metastatic function in colon, liver, and breast can-
cers. [3-5] However, OPN dependent signal transduction
pathways have not been extensively studied in an in vivo
setting.
Recently, we utilized an OPN directed RNA aptamer
(OPN-R3) to inhibit in vivo and in vitro metastatic func-
tion of the MDA-MB231 human breast cancer cell line.[6]
Our results indicated that RNA aptamer binding of OPN
blocks interaction with its cell surface receptors to signifi-
cantly inhibit adhesion, migration and invasion in vitro
and local progression and distant metastases in an in vivo
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xenograft model. In the present study, we sought to build
on our previous observations by determining alterations
in the OPN-dependent signal transduction pathways that
are mediated by RNA aptamer targeting of secreted OPN.
Using specimens from our in vivo xenograft model of
MDA-MB231 human breast cancer, we performed micro-
array analysis to compare the transcriptomes of primary
tumor in the presence and absence of aptamer ablation of
OPN. The microarray results were then corroborated with
RT-PCR and Western blot analysis. Our data demonstrate
that ablation of OPN cell surface receptor binding is asso-
ciated with significant alteration in gene expression criti-
cal in apoptosis, vascular endothelial growth factor
(VEGF), platelet derived growth factor (PDGF), inter-
leukin-10 (IL-10), granulocyte-macrophage colony stimu-
lating factor (GM-CSF) and proliferation signaling
pathways. Many of these proteins have not been previ-
ously associated with OPN in breast cancer. We conclude
that secreted OPN regulates multiple signal transduction
pathways critical for local tumor progression in this in
vivo model of human breast cancer.
Methods
RNA aptamer and systematic evolution of ligands by
exponential enrichment (SELEX): The SELEX selection
procedure was utilized to isolate candidate OPN aptam-
ers, as described previously.[7,8] After each round of
SELEX, we performed a binding affinity assay to measure
the aptamer pool's Kd value to ensure that the Kd values
exhibited a decreasing trend. We applied SELEX by alter-
nating the bait protein between human OPN and mouse
OPN in order to achieve RNA aptamer targeting to com-
mon features of both proteins. The DNA sequence used
for in vitro transcription was 5'-GGGGGAATTCTAATAC-
GACTCACTATAGGGAGGACGATGCGG-N40-CAGAC-
GACTCGCTGAGGATCCGAGA-3', where N40 represents
the 40 nt RNA aptamer library sequence. The sequences





where C denotes 2-OMe-dCTP and U denotes 2-OMe-
dUTP, as appropriate. Commercially synthesized OPN-R3
aptamers contain 2'-OMe C, 2'-OMe U, A, and G and were
used for in vivo studies.
In vivo OPN-R3 activity
Animal handling and procedures were approved by the
Duke University Animal Care and Use Committee. 6-week
old female NOD scid mice were obtained from the Jack-
son Laboratory, Bar Harbor, ME. 1 × 106 MDA-MB-231-
luciferase-expressing cells (a gift of Dr. Mark Dewhirst,
Duke University, NC) were suspended in 50% Matrigel-
Hanks balanced salt solution and implanted into the R4
or L4 positions of the mice mammary fat pad. Modified
OPN-R3 and Mutant OPN-R3 (500 mg/kg) were injected
into the mouse tail vein every two days following cell
implantation. Mice were anesthetized with intraperito-
neal ketamine (75 mg/kg) and xylazine (10 mg/kg) and
subjected to bioluminescent imaging twice weekly to fol-
low tumor progression. The volume of the primary
tumors were quantified with caliper measurements in two
dimensions and tumor volume (V) calculated using the
following formula: V = (1/2) S2 × L (S, the shortest dimen-
sion; L, the longest dimension). Primary tumor tissues
were excised from OPN-R3 and Mutant OPN-R3 treated
mice.
cDNA microarray analysis
Total RNA was extracted from primary tumor using RNe-
asy mini kit (Qiagen, Valencia, CA). A total of nine ani-
mals were used (WT, n = 3; OPN-R3, n = 3; Mutant OPN-
R3, n = 3). The cDNA synthesis, labeling, hybridization
and scanning were performed by the Duke University
Microarray Facility. The Human Operon v4.0 spotted
array covering 35 k human genes was used; The complete
description of the array is available at http://
www.genome.duke.edu/cores/microarray. Samples from
each animal were arrayed separately. The raw microarray
data can be accessed at https://discov
ery.genome.duke.edu/express/resources/1515/
Kuolab.xls. Microarray data were analyzed by the Partek
Genomics Suite software (Partek, St. Louis, MO). Gene
expression signal pathways were analyzed with the Inge-
nuity Pathways Analysis software (Ingenuity Systems,
Redwood City, CA).
Real-time PCR analysis
Real-time PCR was performed with the two-step reaction
protocol using iQ SYBR Green detection kit (Bio-Rad Lab-
oratories, Hercules, CA). First-strand cDNA were synthe-
sized from 1-mg total RNA using the iScript Select cDNA
synthesis kit (Bio-Rad Laboratories, Hercules, CA) at
48°C for 30 min. Glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) was used as the endogenous control.
The primer sets were used for the quantitative PCR analy-
sis are listed in Table 1. Real-time PCR parameters used
were as follows: 95°C for 3 min; 95°C for 30 s, 55°C for
35 s for 40 cycles; 95°C for 1 min, and 55°C for 10 min.
PCR was performed with iQ SYBR Green super mix, using
the iCycler iQ Real-time PCR Detection System (Bio-Rad
Laboratories, Hercules, CA). The 2-delta-delta Ct value
was calculated following GAPDH normalization.
Western blot analysis
Western blot analysis was performed as previously
described.[9] The membranes were probed with the fol-
lowing primary antibodies for 1 h at room temperature:BMC Research Notes 2009, 2:119 http://www.biomedcentral.com/1756-0500/2/119
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Src Ab (Cell Signaling, Beverly, MA), HIF-1 Ab, VEGF Ab,
PDGF Ab, b-Catenin Ab, STAT3 Ab, CAMK2A Ab, OSM
Ab, BTG3-b Ab, CD82 Ab, GAPDH Ab (Santa Cruz Bio-
technology, Santa Cruz, CA), BCL-2-like 1 Ab, HO-
1(Sigma-Aldrich, Atlanta, GA). Following exposure to
horseradish peroxidase-conjugated secondary antibody,
reactive proteins were visualized by means of the ECL kit
(Amersham Biosciences, Piscataway, NJ).
Statistical analysis
For microarray data analysis, the raw intensity values were
exported to GeneSpring GX 10 software (Agilent Technol-
ogies, Santa Clara, CA). Normalization was achieved
using a Z score transformation method on GeneSpring 10
software. This method ultimately produced a distribution
of Z scores for all the genes in each array, and used the dif-
ferences in the Z scores to calculate Z ratios to locate genes
that were expressed differentially. The student t-test was
applied for p-value calculation. Genes that had a Z ratio >
1.5 and a p-value < 0.005 were considered significant.
Results and Discussion
We have previously demonstrated that the RNA aptamer,
OPN-R3, blocks interaction with its cell surface receptors
resulting in significantly decreased: 1) expression of
MMP2 and uPA, 2) activation of CD44 and avb3 depend-
ent signal transduction pathways, 3) in vitro measures of
adhesion, migration and invasion, and 4) in vivo local
progression and distant metastases in a xenograft
model.[6] Bioluminescence was significantly decreased in
the OPN-R3 treated animals by over 4- and 12-fold at 20
and 30 days post-implantation, respectively. (p < 0.01 at
20 days and 30 days for OPN-R3 vs Mutant OPN-R3 and
Vehicle) At day 20, tumor volume in the OPN-R3 aptamer
Table 1: Real-time PCR Primer Sets
GAPDH: forward:5'-AGCCTCAAGATCATCAGCAATGCC-3',
reverse: 5'-TGTGGTCATGAGTCCTTCCACGAT-3'.










B-cell CLL/lymphoma-2 (BCL-2): forward: 5'-GAGGTGATCCCCATGGCAGC-3',
reverse: 5'-TGTCCCTGGGGTGATGTGGA-3'
Heme-oxygenase-1 (HO-1): forward: 5'-TGTACCACATCTATGTGGCC-3',
reverse: 5'-CCAGGTCCTGCTCCAGGGCA-3'
Signal Transducers and Activator of Transcription 3 (STAT3): forward: 5'-CAGCAGATGCTGGAGCAGCA-3',
reverse: 5'-CTTGAGGGTTTTATAGTTGA-3'
Oncostatin-M (OSM): forward: 5'-GAAGCAGACAGATCTCATGC-3',
reverse: 5'-CTCCCTGCAGTGCTCTCTCA-3'
Calmodulin-dependent protein kinase-2A (CAMK2A): forward: 5'-GGAAGCCAAGGATCTGATCA-3',
reverse: 5'-TGCATGCAGGATGCCACGGT-3'
B-cell translocation gene-3b (BTG3-b): forward: 5'-AGGACAGGCCTACAGATGTA-3',
reverse: 5'-GAGAGTGAGCTCCTTTGGCA-3'
Cluster of Differentiation 82 (CD82): forward: 5'-AGAGCAGTTTCATCTCTGTC-3',
reverse: 5'-GCAGCCCAGGAAGCCCATGA-3'BMC Research Notes 2009, 2:119 http://www.biomedcentral.com/1756-0500/2/119
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treated group was > 18 fold smaller than that of Mutant
OPN-R3 and Vehicle groups. (p < 0.01 vs. Mutant OPN-
R3 and Vehicle) At day 30, OPN-R3 aptamer treated group
tumor was 8-fold less than that of the Mutant OPN-R3
and the Vehicle groups. (p < 0.01 vs. Mutant OPN-R3 and
Vehicle) These data indicate that OPN-R3 aptamer can sig-
nificantly decrease local tumor growth of MDA-MB231
cells in this xenograft model and were previously
reported.
Based upon our previously published findings (as
detailed above), we next sought to identify the genes
whose expression is regulated by OPN in this model, we
extracted RNA from primary tumor from untreated (WT)
animals and those treated with OPN-R3 and Mutant
OPN-R3. The reference set was defined to be the mean of
the WT and Mutant OPN-R3 groups. The heat map of the
three groups and the scatter plots of WT versus Mutant
OPN-R3 and OPN-R3 versus Mutant OPN-R3 are dis-
Gene expression profiling Figure 1
Gene expression profiling. A. Microarray heat map analysis of mouse primary tumors treated by OPN-R3(left); wild type 
non-treatment (middle) and Mutant OPN-R3 aptamer. The panel shows gene expression fold change compared with the mean 
normalized value of controls (wild type non-treatment and mutant OPN-R3 aptamer treatment). The intensity of the node 
color indicates the degree of increase (red) or decrease (blue) gene expression. B, C. Scatter plots showing differentially 
expressed genes between mutant OPN-R3 aptamer treatment and OPN-R3 aptamer treatment (B) and between wild type 
non-treatment and mutant OPN-R3 treatment control(C). D. List of the dysregulated genes associated with down regulated 
and up regulated canonical signal transduction pathways.BMC Research Notes 2009, 2:119 http://www.biomedcentral.com/1756-0500/2/119
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Ingenuity Pathways Analysis Figure 2
Ingenuity Pathways Analysis. The bar graphs indicate down regulated and up regulated canonical pathways associated with 
OPN-R3 aptamer treatment. A. Four down regulated canonical biochemical and molecular biology pathways with significant (p 
< 0.05, Fisher's exact test) correlation in comparison to the wild type non-treatment and Mutant OPN-R3 aptamer treatment 
controls. B. Four up regulated canonical biochemical and molecular biology pathways with significant (p < 0.05, Fisher's exact 
test) correlation in comparison to the wild type non-treatment and Mutant OPN-R3 aptamer treatment controls.BMC Research Notes 2009, 2:119 http://www.biomedcentral.com/1756-0500/2/119
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Verification of Microarray Results Figure 3
Verification of Microarray Results. A. Histogram of mRNA changes in MDA-MB231 primary tumor from animals treated 
with OPN-R3 and/or Mutant OPN-R3. Real-time PCR was performed and the 2-delta-delta Ct value was calculated following 
GAPDH normalization. Fold induction was determined relative to cells treated with Mutant OPN-R3. A total of six animals 
were analyzed (OPN-R3, n = 3; Mutant OPN-R3, n = 3). Data are representative of three experiments. B. Western blots of dif-
ferentially expressed proteins in MDA-MB231 primary tumor from animals treated with OPN-R3 and/or Mutant OPN-R3. 
Blots are representative of three experiments.BMC Research Notes 2009, 2:119 http://www.biomedcentral.com/1756-0500/2/119
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played in Figure 1. The scatter plots indicate that signifi-
cant differences in gene expression are present between
the OPN-R3 and Mutant OPN-R3 groups, while the WT
and Mutant OPN-R3 groups are not significantly different.
The top eight genes down-regulated by >2-fold and the
top four genes up-regulated by >2-fold primary tumors
from OPN-R3 treated animals are listed in Figure 1D.
Genes were then assigned to biological pathways using
Ingenuity Pathway software. (Figure 2) The threshold
value of -log (p-value) was set at 1.31, corresponding to a
p-value of 0.05. This software suggests that OPN-R3 was
associated with down regulation of IL-10, VEGF, PDGF
and anti-apoptosis signaling with concomitant up regula-
tion of apoptosis, GM-CSF, anti-proliferative and anti-
metastasis signaling pathways.
The microarray data suggest that OPN-R3 treatment was
associated with decreased expression of genes involved in
IL-10 (HO-1, STAT3), VEGF (HIF-1a, VEGF), PDGF
(PDGF-a, Src) and anti-apoptosis (b-catenin, BCL-2 like
protein) signaling and increased expression of genes
involving apoptosis (CAMK2A), GM-CSF (OSM), anti-
proliferative (BTG3-b) and anti-metastasis (CD82) signal-
ing. Real-time RT-PCR and Western blot analysis were
used to verify altered expression of the identified genes
and proteins in OPN-R3 and Mutant OPN-R3 groups. RT-
PCR corroborated the microarray results. (Figure 3A) Sim-
ilarly, expression of the corresponding proteins were also
altered in a fashion predicted by the microarray results.
(Figure 3B) These results demonstrate that blockade of
OPN binding through RNA aptamer targeting decreases
expression of key proteins involved in the IL-10, VEGF,
PDGF and anti-apoptosis pathways with simultaneous
increases in apoptosis, GM-CSF, anti-proliferative and
anti-metastasis signaling proteins.
OPN was initially characterized in 1979 as a phosphopro-
tein secreted by transformed, malignant epithelial
cells.[10,11] It is a member of the small integrin-binding
ligand N-linked glycoprotein (SIBLING) family of pro-
teins which include bone sialoprotein (BSP), dentin
matrix protein 1 (DMP1), dentin sialoprotein (DSPP),
and matrix extracellular phosphoglycoprotein
(MEPE).[1,12,13] The molecular structure of OPN is rich
in aspartate and sialic-acid residues and contains unique
functional domains which mediate critical cell-matrix and
cell-cell signaling through the avb3 integrin and CD44
receptors in a variety of normal and pathologic processes.
[14-19] As a secreted protein, OPN represents an ideal tar-
get for OPN-R3 aptamer mediated inhibition. In this
study examining the transcriptomes of primary tumors
from OPN-R3 treated animals, we show that ablation of
OPN cell surface binding decreases expression of key pro-
teins involved in the IL-10, VEGF, PDGF and anti-apopto-
sis pathways with simultaneous increases in apoptosis,
GM-CSF, anti-proliferative and anti-metastasis signaling
proteins. These results indicate the wide ranging effects of
OPN in regulating critical pathways required for local
tumor growth and metastasis.
Review of the specific genes identified in this study indi-
cates that, in certain instances, associations with OPN and
cancer have been identified in the past. For example, Src is
a well recognized member of the signal transduction path-
way associated with OPN binding to CD44.[6] However,
the relationship between OPN and other genes is not as
well characterized. Recently, in a variety of in vitro and in
vivo assay using MDA-MB-231 cells, Chakraborty et al.
found that OPN plays a key role in VEGF expression and
VEGF-stimulated neovascularization.[20,21] In advanced
head-and-neck cancer, a poor prognosis correlated with
parallel increases in both OPN and HIF-1a. [22,23] Sid-
diqui and coworkers found that STAT3 was increased
while OPN was decreased in response to green tea
polyphenol in a mouse model of prostate cancer.[24] In a
nude mouse model of hepatocellular cancer, Zhao and
colleagues demonstrated that OPN silencing using shRNA
inhibited BCL-2 protein expression.[5] The relationship
between b-catenin and OPN has been extensively docu-
mented.[1,25-27] T cell factor 4 (Tcf-4) interacts with
beta-catenin in the Wnt signaling pathway and coactivates
downstream target genes in the breast. In a rat model for
breast cancer, it has been shown that metastasis-inducing
DNA sequesters the endogenous inhibitory Tcf-4 and
thereby promotes transcription of OPN.[1,27] However,
at present, it is unclear why ablation of extracellular OPN
would result in decreased b-catenin mRNA and protein
expression. Many of the studies merely document associ-
ations without demonstration of causality or delineation
of mechanism. HO-1, OSM, CAMK-2, CD82, BTG3-b and
PDGF have not been previously linked with OPN in the
setting of cancer.
While these results require confirmation in other cell
types and human tissues, our study indicates that OPN
regulates the local growth and metastasis through a com-
plex multi-faceted signaling network. Characterization of
these pathways using our functional model identifies
potential targets for future therapies directed agaqinst
OPN signaling in breast cancer.
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